What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna’s post-pandemic future was thrown into question Thursday after it disclosed multiple setbacks that disappointed investors. The biotech company has been largely shut out of the COVID ...

In morning trades, Moderna stock rose nearly 4% to 28.22 ... support rapid response in a future influenza pandemic, and pave ...

Moderna president Stephen Hoge knows investors are waiting to see the company grow in a big way and regain the momentum lost following outsized COVID-19 vaccine revenues.

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines.

These ratings convey expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...

Moderna Inc.’s third-quarter revenue fell by nearly a third and the pharmaceutical company cut its outlook, saying as part of its earnings report that supply constraints for its Covid-19 ...

Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.

Moderna’s new TV spot, “Welcome to the mRNAge," is here to let people know that messenger RNA vaccines are not just a one trick (COVID-19) pony.